<DOC>
	<DOCNO>NCT00715858</DOCNO>
	<brief_summary>The purpose study examine cerebrospinal fluid ( CSF ) patient Alzheimer 's disease biomarkers inflammation response antibiotic doxycycline rifampin . The result preliminary analysis use define direction research .</brief_summary>
	<brief_title>A Pilot Study Inflammatory Markers Alzheimer 's Disease</brief_title>
	<detailed_description>Doxycycline rifampicin two antibiotic may useful treatment Alzheimer 's disease ( AD ) . Besides antimicrobial effect may also decrease specific contributor AD pathology include : 1. amyloid beta , 2. inflammatory mediator , 3. proteolytic enzyme , 4. metal ion . Evidence indicate inflammatory response AD . This include complement activation , elevate C-reactive protein ( CRP ) , elevate pro-inflammatory cytokine ( include IL-1-beta , IL-6 , TNF-α , TGF-β , S100-β ) , chemokine alteration ( IL-8 , MIP-1-alpha , MIP-1-beta , MCP-1 ) , microglial activation . In previous study AD patient treat combined doxycycline rifampicin versus placebo , demonstrate antibiotic treatment significantly delay progression clinical impairment . Treatment also reduce blood CRP level suggest anti-inflammatory role antibiotic . In study suggest analysis biomarkers include pro anti-inflammatory cytokine TNF-alpha , IL-1beta , IL-4 , IL-10 , chemokine MCP-1 inflammatory marker cerebrospinal fluid ( CSF ) blood AD patient age-matched control . AD patient participant 12 month randomize clinical trial doxycyline rifampin placebo ( DARAD ) treatment AD . Each patient ask wish contribute sample CSF blood baseline 12 month treatment complete . About half patient consent . Since consent give lumbar puncture double-blinded DARAD treatment initiate , expect distribution sample collect random among four treatment group . We compare CSF biomarker level among four treatment group . Ten age-matched healthy control also ask contribute CSF blood sample comparison . The control participant DARAD trial . We feel important pilot study determine whether difference blood CSF concentration commonly study cytokine AD patient normal control . As , study could contribute search diagnostic biomarker . Also , could provide solid foundation future study aim elucidate effect antibiotic various biomarkers blood CSF AD patient . From , may able correlate previous finding antibiotic delay progression clinical outcome AD change blood CSF biomarker level .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Giving informed consent lumbar puncture Participation DARAD clinical trial require follow : diagnosis probable Alzheimer 's disease SMMSE 1426 inclusive communitydwelling age 50 great caregiver monitor study medication report ADLs , behaviour , etc . adequate English literacy complete neuropsychological test generally stable level health Contraindication lumbar puncture DARAD exclusion criterion follow : dementia due neurodegenerative disease cognitive impairment due head trauma , etc . stroke significant cerebrovascular disease clinically significant cardiac disease recent MI , uncontrolled hypertension take antidementia treatment investigational drug allergy doxycycline rifampin significant psychiatric condition like depression cancer</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>dementia</keyword>
	<keyword>inflammation</keyword>
	<keyword>cytokine</keyword>
	<keyword>biomarker</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>serum</keyword>
	<keyword>doxycycline</keyword>
	<keyword>rifampin</keyword>
</DOC>